Breaking News

FDA Approves argenx’s VYVGART Hytrulo Prefilled Syringe for Self-Injection

Patients can self-inject after proper instruction in subcutaneous injection technique.

Author Image

By: Charlie Sternberg

Associate Editor

Argenx’s VYVGART Hytrulo prefilled syringe for self-injection (efgartigimod alfa and hyaluronidase-qvfc) has received U.S. FDA approval for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive and adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). VYVGART Hytrulo prefilled syringe for self-injection is approved as a 20-to-30-second subcutaneous injection administered by a patient, careg...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters